| __timestamp | Catalyst Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 10117774 | 55430000 |
| Thursday, January 1, 2015 | 11801342 | 65510000 |
| Friday, January 1, 2016 | 11369941 | 71160000 |
| Sunday, January 1, 2017 | 11375237 | 70644000 |
| Monday, January 1, 2018 | 19919204 | 70418000 |
| Tuesday, January 1, 2019 | 18842752 | 63238000 |
| Wednesday, January 1, 2020 | 16496715 | 59777000 |
| Friday, January 1, 2021 | 16936000 | 60152000 |
| Saturday, January 1, 2022 | 19789000 | 54540000 |
| Sunday, January 1, 2023 | 93150000 | 52243000 |
| Monday, January 1, 2024 | 64536000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Catalyst Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Catalyst Pharmaceuticals increased its R&D expenses by over 800%, peaking in 2023. This surge underscores their aggressive strategy to expand their drug pipeline. In contrast, Taro Pharmaceutical's R&D spending remained relatively stable, with a slight decline of about 6% from its peak in 2016. This consistency reflects a more conservative approach, focusing on optimizing existing products. Notably, 2024 data for Catalyst Pharmaceuticals is missing, leaving room for speculation on their future strategy. As these companies navigate the evolving pharmaceutical landscape, their R&D investments will continue to shape their competitive edge.
Research and Development Investment: Johnson & Johnson vs Catalyst Pharmaceuticals, Inc.
Comparing Innovation Spending: Gilead Sciences, Inc. and Catalyst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Incyte Corporation vs Taro Pharmaceutical Industries Ltd.
R&D Insights: How Bio-Techne Corporation and Catalyst Pharmaceuticals, Inc. Allocate Funds
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
Research and Development Investment: Pharming Group N.V. vs Catalyst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Pharming Group N.V. vs Taro Pharmaceutical Industries Ltd.
Research and Development Expenses Breakdown: Grifols, S.A. vs Catalyst Pharmaceuticals, Inc.
Research and Development Investment: Grifols, S.A. vs Taro Pharmaceutical Industries Ltd.
Who Prioritizes Innovation? R&D Spending Compared for Corcept Therapeutics Incorporated and Catalyst Pharmaceuticals, Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.
R&D Insights: How MannKind Corporation and Taro Pharmaceutical Industries Ltd. Allocate Funds